The MDS Beacon™

Leave a comment

News

Resources

Links

Most Recent Comments

• Beacon Staff: Thank you for the feedback, R Denningham. We are sorry if it seems that we are favoring Revlimid in our...
• R Denningham: There are too many reports that appear to be promotions for Celgene’s REVLIMID therapy. For...
• Daniel V Grant: I was diagnosed with MDS this past March and I have responded very well to VIDAZA. My blood counts...
• Alan: Benzene exposure can cause some forms. My mother has a form called 5q deletion. God Bless al of you who have...
• ALMOST THERE: Here’s a hero once again, showing his inner fight to survive! The government my friend, is tough...

Subscribe

• Subscribe to our RSS feed
• Get Beacon News by Email
• Become our fan on Facebook!
• Follow us on Twitter!

News Archives

• ▼2010 (70)
  • ▼ September (1)
    • Pre-Transplant Conditioning With Treosulfan And Fludarabine May Be Effective And Safe For MDS Patients
  • ► August (10)
    • Stem Cell Transplants For Myelodysplastic Syndromes – Part 4: Patient Experiences (Sibling Donors)
    • Patient Stem Cells Remaining After Donor Transplant May Predict Relapse Of Myelodysplastic Syndromes
    • Beacon NewsFlashes – August 23, 2010
    • Stem Cell Transplants For Myelodysplastic Syndromes – Part 3: Benefits & Risks
    • Preventative Antibiotic Treatment May Reduce Fever In MDS Patients Treated With Dacogen
    • Stem Cell Transplants For Myelodysplastic Syndromes – Part 2: Procedure
    • Serum Albumin Levels After Stem Cell Transplantation May Be A Good Prognostic Factor For MDS Patients
    • Beacon NewsFlashes – August 6, 2010
    • Stem Cell Transplants For Myelodysplastic Syndromes – Part 1: Introduction & Types Of Transplants
    • Cyclosporine And Thalidomide Combination Therapy Is Effective And Safe For MDS Patients
  • ► July (9)
    • Beacon NewsFlashes - July 29, 2010
    • Intensity, Not Total Number, Of Red Blood Cell Transfusions May Be Linked To Poor MDS Prognosis (EHA 2010)
    • Treosulfan-Based Treatment Prior To Stem Cell Transplants Shows Promise For MDS Patients
    • Vidaza Treatment Effective And Safe In All Elderly MDS Patients (EHA 2010)
    • Vitamin K2 And Vitamin D3 Combination Therapy May Increase Red Blood Cell and Platelet Counts In Low-Risk MDS Patients
    • Personal Perspective: College Professor Keeps Busy While Living With Myelodysplastic Syndromes
    • Vidaza Or Dacogen Treatment May Be Effective In MDS Patients Before Stem Cell Transplantation (EHA 2010)
    • MDS Patients With Impaired Kidney Function Can Be Treated With Vidaza And Dacogen
    • Researchers Confirm Link Between Severity Of Anemia And Survival In MDS Patients (EHA 2010)
  • ► June (10)
    • Elderly MDS Patients With Other Diseases Respond Well To Vidaza Treatment And Do Not Experience Additional Side Effects (EHA 2010)
    • MDS Research Presented At The 15th Congress Of The European Hematology Association (EHA 2010)
    • Belinostat Alone Is Not An Effective Myelodysplastic Syndromes Treatment (ASCO 2010)
    • Revlimid Side Effects In Myelodysplastic Syndromes Patients Are Manageable And Decrease With Extended Treatment (ASCO 2010)
    • Continued Vidaza Treatment In MDS Patients With Stable Disease May Lead To An Improved Response And Longer Survival (ASCO 2010)
    • Intravenous Clolar Shows Activity In Higher-Risk Myelodysplastic Syndromes (ASCO 2010)
    • ASCO 2010 Myelodysplastic Syndromes Update – June 7
    • ASCO 2010 Myelodysplastic Syndromes Update – June 5 & 6
    • New Data Presented On Sapacitabine As A Treatment For Refractory Myelodysplastic Syndromes (ASCO 2010)
    • Anemia in Myelodysplastic Syndromes
  • ► May (8)
    • Latest MDS Research To Be Presented At The American Society Of Clinical Oncology’s 2010 Annual Meeting (ASCO 2010)
    • Myelodysplastic Syndromes More Common Than Previously Estimated
    • Vidaza Improves Survival in Elderly Myelodysplastic Syndromes Patients
    • Personal Perspective: Vietnam Vet Fights Myelodysplastic Syndromes To Spend More Time Outside
    • Oral Clolar May Be An Effective Therapy For Higher-Risk Myelodysplastic Syndromes
    • Guide To Clinical Trials For Myelodysplastic Syndromes Patients – Part 3: Participating In Clinical Trials
    • Aranesp Reduces Symptoms Of Anemia And Improves Quality Of Life For Myelodysplastic Syndromes Patients
    • Beacon NewsFlashes - May 4, 2010
  • ► April (10)
    • Guide To Clinical Trials For Myelodysplastic Syndromes Patients – Part 2: Benefits And Risks Of Clinical Trials
    • Awareness And Management Of Vidaza Side Effects May Contribute To Treatment Success In Myelodysplastic Syndromes Patients
    • Beacon NewsFlashes – April 21, 2010
    • Guide To Clinical Trials For Myelodysplastic Syndromes Patients – Part 1: Learning About Clinical Trials
    • White Blood Cell Counts May Help Assess Prognosis In Myelodysplastic Syndromes
    • Immunosuppressants May Increase Responsiveness To Erythropoietin In Anemic Myelodysplastic Syndromes Patients
    • Chromosomal Abnormalities Affect Prognosis In Myelodysplastic Syndromes
    • Review Of Treatment Options For High-Risk Myelodysplastic Syndromes Patients
    • Revlimid And Vidaza Combination May Be Effective In Treatment Of High-Risk MDS
    • Caring For A Loved One With Myelodysplastic Syndromes – Part 4: From A Patient’s Perspective
  • ► March (9)
    • Underlying Disease Is Greatest Risk Factor For Low-Risk Myelodysplastic Syndromes
    • Myelodysplastic Syndromes Patients With Skin Lesions Have Slightly Higher Risk of Disease Progression
    • Caring For A Loved One With Myelodysplastic Syndromes – Part 3: Loss, Grief, And Bereavement
    • Lymphocyte Count May Be Good Prognostic Factor For Survival In Myelodysplastic Syndromes Patients
    • FDA Approves New Dacogen Dosing Schedule For Myelodysplastic Syndromes
    • Caring For A Loved One With Myelodysplastic Syndromes – Part 2: Doctor Appointments
    • Trisomy 11 In Myelodysplastic Syndromes May Be An Indicator Of Higher-Risk MDS And Shorter Survival
    • Beacon NewsFlashes — March 5, 2010
    • Nplate May Be Effective In Treating Thrombocytopenia In Myelodysplastic Syndromes Patients
  • ► February (6)
    • Caring For A Loved One With Myelodysplastic Syndromes – Part 1: Making Your Own Health A Priority
    • Exjade Not Recommended For High-Risk Myelodysplastic Syndromes Patients
    • Recombinant Erythropoietin Alpha Without Granulyte-Colony Stimulating Factor Produces Longer Survival In Myelodysplastic Syndromes Patients
    • Study Shows Successful Stem Cell Transplantation For Elderly Myelodysplastic Syndromes Patients Depends On Disease Stage, Not Age
    • Molecular Analysis May Explain Why Dacogen Alone And Dacogen Plus Valproic Acid Show Similar Response Rates (ASH 2009)
    • Vidaza and Enbrel Combination Therapy May Improve Response In Myelodysplastic Syndromes Patients
  • ► January (7)
    • Beacon NewsFlashes - January 27, 2010
    • Vidaza and Thalidomide Combination Therapy Shows No Unexpected Side Effects In Myelodysplastic Syndromes Patients (ASH 2009)
    • Vidaza May Be Safe And Effective In MDS Patients Of All Ages (ASH 2009)
    • Dacogen Is Safe And Effective In Older Myelodysplastic Syndromes Patients (ASH 2009)
    • Vidaza and Thalidomide Combination Therapy Is Safe And At Least As Effective As Vidaza Alone In Myelodysplastic Syndromes Patients
    • Researchers Observe High Survival Time For Myelodysplastic Syndromes Patients With Deletion 5q (ASH 2009)
    • Study Finds Vfend A Good Alternative For Fungal Infection Prevention In Myelodysplastic Syndromes
• ►2009 (84)
  • ► December (11)
    • Trisenox May Be Effective In MDS (ASH 2009)
    • Recommended Revlimid Starting Dose Is More Effective Than Low-Dose Revlimid For Myelodysplastic Syndromes (ASH 2009)
    • MDS Patients Are Responsive To Sapacitabine, According To Interim Phase 2 Study Results (ASH 2009)
    • Approved Vidaza Dosing Schedule May Be Better And Safer Than Alternatives (ASH 2009)
    • Beacon NewsFlashes – December 13, 2009
    • Clolar Shows Promise As Myelodysplastic Syndromes Treatment, According To Research Review
    • Phase 2 Study Shows Campath Improves Blood Cell Production For Myelodysplastic Syndromes Patients (ASH 2009)
    • Study Shows Revlimid Reduces Chromosomal Abnormalities For Del-5q Myelodysplastic Syndromes Patients (ASH 2009)
    • The Public Is Encouraged To Comment On Potential Medicare Coverage Of Bone Marrow Transplants For Myelodysplastic Syndromes Patients
    • Velcade May Be Effective In Treating MDS (ASH 2009)
    • Research Validates Possible New Grouping Scheme For MDS Patients Undergoing Stem Cell Transplants
  • ► November (8)
    • Revlimid Alternate-Day Dosing Regimen Shows Promise In Myelodysplastic Syndromes
    • Latest MDS Research To Be Presented At The 51st Meeting Of The American Society Of Hematology (ASH 2009)
    • Reduced-Intensity Drug Regimens Allow Stem Cell Transplantation In Elderly MDS Patients
    • Complication, Acute Pulmonary Failure, Is Associated With Chemotherapy For MDS Patients
    • Ban On Payment For Bone Marrow Donations Challenged In Lawsuit
    • Response After Revlimid Treatment Predicts Risk For AML In Certain Myelodysplastic Syndromes Patients
    • The H1N1 Swine Flu Vaccine And Myelodysplastic Syndromes: A Comprehensive Review
    • Beacon NewsFlashes – November 3, 2009
  • ► October (9)
    • Gene RPS14 Is Linked To Survival Of Patients With Myelodysplastic Syndromes
    • Valproic Acid May Enhance Efficacy Of Vidaza For Myelodysplastic Syndromes
    • Five-Day Intravenous Vidaza For MDS Shows Mixed Results Compared To Standard Dosing Regimen
    • Beacon NewsFlashes - October 15, 2009
    • Personal Perspective: Blogging About Skiing, Golfing, And Airplanes - And Living With MDS
    • Evening Primrose Oil Alleviates Vidaza Injection Site Irritation
    • Study Finds Lower-Risk MDS Patients Benefit From Erythropoietin Treatments
    • Beacon NewsFlashes - October 2, 2009
    • Study Finds Dacogen And Vidaza Better Than Conventional Care For MDS Patients
  • ► September (12)
    • FDA Analyzing Safety Of Exjade In MDS Patients
    • Beacon BreakingNews - FDA Examining Exjade Safety In MDS Patients
    • Smokers At Higher Risk For Developing Myelodysplastic Syndromes
    • Beacon NewsFlashes – September 25, 2009
    • Iron-Reducing Therapy May Extend Lives Of MDS Patients
    • Revlimid Prescribing May Vary For Different Chromosome 5 Abnormalities
    • H1N1 Swine Flu Vaccinations Recommended For Patients With Myelodysplastic Syndromes
    • New Differences Found In Chinese And Western MDS Patients
    • Patients With Myelodysplastic Syndromes Prefer To Be Transfusion-Independent
    • Beacon NewsFlashes – September 8, 2009
    • Different Prognoses Found For MDS Patients With Chromosome 5 Abnormalities
    • Study Reveals One Fifth Of MDS Patients In The U.K. Are Unable To Receive Life-Extending Treatment
  • ► August (9)
    • Beacon NewsFlashes - August 31, 2009
    • Statistical Results Revealed From Study Of MDS Patients In Romania
    • MDS Patients Dependent On Multiple Transfusions Have Shorter Survival Time
    • Canadian Myelodysplastic Syndromes Patient Seeks Help In United States
    • Beacon NewsFlashes – August 13, 2009
    • Vidaza Upgraded To Preferred Treatment For High-Risk MDS Patients
    • Beacon NewsFlashes - August 7, 2009
    • Beacon SiteUpdate – The MDS Beacon Has A New Design
    • United Kingdom May Halt Funding For Vidaza
  • ► July (16)
    • Beacon NewsFlashes – July 27, 2009
    • Treatment Of Myelodysplastic Syndromes With Dacogen May Cause Fluid Build-Up
    • Amifostine Promotes Improved Blood Production In Some Myelodysplastic Syndromes Patients
    • Chromosome Abnormalities May Predict Success Of Chemotherapy On Patients With Myelodysplastic Syndromes
    • Study Suggests Association Between T-cell Imbalance And Response To Immunosuppressive Therapy In MDS Patients
    • Phase 2 Study Shows Immunosuppressive Treatment Is Safe And Effective For Myelodysplastic Syndromes And Aplastic Anemia
    • German Study Emphasizes Importance Of Multiple Tests For MDS Diagnosis
    • Vidaza Most Effective When First-Choice Treatment (ASCO 2009)
    • MDS Patients’ Pretreatment Risk Level Predicts Outcome Of Vidaza Treatments (EHA 2009)
    • Flow Cytometry Useful For Accurately Diagnosing Myelodysplastic Syndromes
    • Stem Cell Transplantation Most Favorable Treatment For Cognitive Function
    • Beacon NewsFlash - July 9, 2009
    • MDS Prevalence May Be Higher Than Previously Thought
    • Vidaza and Dacogen Effective In MDS Patients With Decreased Kidney Function (ASCO 2009)
    • Nplate Effective For Increasing Platelet Counts In MDS Patients (ASCO 2009)
    • Beacon NewsFlashes – July 1, 2009
  • ► June (13)
    • Obesity And Smoking Linked To Myelodysplastic Syndromes
    • Allogeneic Hematopoietic Cell Transplantation Effective For The Elderly (EHA 2009)
    • Transfusion Independence Linked To Increased Vidaza Treatment Cycles (EHA 2009)
    • Beacon NewsFlashes - June 16, 2009
    • Mutated Gene Sequence Linked To Blood Disorders Such As MDS
    • Recurring Sweet Syndrome Linked To MDS
    • Thalidomide Effective In Low-Risk MDS Patients (EHA 2009)
    • Vidaza and Dacogen Improve Overall Survival Of MDS Patients (EHA 2009)
    • Immune System Increasingly Linked To MDS (ISMDS 2009)
    • Personal Perspective: "I Have MDS."
    • Phase 2 Study Shows Combination Therapy Of Zolinza With Idarubicin And High-Dose Cytarabine Effective For MDS (ASCO 2009)
    • Studies Show Improvement With Increased Dacogen Treatment Cycles (ASCO 2009)
    • Study Shows Iron Chelating Properties Of Wheat Grass Juice (ASCO 2009)
  • ► May (6)
    • MDS Treatments Discussed At ASCO’s 45th Annual Meeting (ASCO 2009)
    • Optimizing Epigenetic Therapies For MDS (ISMDS 2009)
    • 10th International Symposium On Myelodysplastic Syndromes Held In Greece
    • Beacon NewsFlashes - May 11, 2009
    • Vidaza, Revlimid Spur Search for New MDS Drugs
    • Welcome To The MDS Beacon